The CU Technology Transfer Office is happy to report that two CU-Boulder faculty members, Hang ‘Hubert’ Yin (BioFrontiers; Chemistry & Biochemistry) and Linda Watkins (Psychology & Neuroscience) recently received a patent for novel drugs modulating the toll-like receptor 4 (TLR4) signaling pathway. These drugs are useful as an independent treatment for chronic pain, and can also be used to help make opioid painkillers (such as Percocet and Vicodin) more effective and less likely to result in addiction and dependency. This technology has been optioned to a publicly-traded biopharma company for further development.
TTO filed this patent application on behalf of the university in September 2009; patent protection is also pending in Europe, Japan and several other regions. The patent (U.S. 8,642,614, “Toll-like Receptor Modulators and Uses Thereof”) was issued on Feb. 4, 2014.